Comparative Pharmacology
Head-to-head clinical analysis: FAYOSIM versus KALLIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAYOSIM versus KALLIGA.
FAYOSIM vs KALLIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
KALLIGA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and easily excreted metabolite, thereby reducing serum uric acid levels.
10 mg orally once daily
0.5 mg orally once daily, titrated to 1 mg once daily after 2-4 weeks if tolerated.
None Documented
None Documented
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
Terminal elimination half-life: 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Renal excretion: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antihistamine
Antihistamine